Divislab 6100 CE Recommended above 320, Sl 302, Trgt 351

Divislab 6100 CE Recommended above 320, Sl 302, Trgt 351
 
Divis Lab has formed an agreement with a global Pharma company for a long-term manufacturing and supply agreement for the Manufacturing and supply of advanced intermediates. The recent agreement with a global pharmaceuticals firm. Under the long-term agreement, the company will be manufacturing and supplying advanced intermediates as per the commercial terms agreed between the parties, Divi's Laboratories said in a regulatory filing.

The company expects meaningful revenue contribution from this long-term agreement, it added without disclosing the identity of the partner.

The company is planning for capacity addition at its manufacturing facilities with an estimated investment between Rs 650 crore to Rs 700 crore, to be funded from internal accruals.
The company reported a 25.01 percent YoY increase in revenue from Rs. 1,855 Crore in Q3FY24 to Rs. 2,319 Crore in Q3FY25. On a QoQ basis, the company reported a decrease of 0.81 percent in revenue from Rs. 2,338 Crore in the previous quarter. Their Net profit saw an increase of 64.52 percent YoY from Rs. 358 Crore to Rs. 589 Crore for the same period. On a QoQ basis, the company reported an increase of 15.49 percent in Net profit from Rs. 510 Crore in the previous quarter.
The stock was in an uptrend since the news flashed. Today, it opened with a gap-up and sustained above its opening range, hence recommended ATM Call option of the near month contract for a small but a quick up-move.